| MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. BU, L. CHEN, R. MCCASKILL, P. ZUEGER, E. MCDEARMON-BLONDELL, A. PANGAN a W. TILLETT. UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY. 2021. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2021-eular.1066. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1841042,
author = {Mease, P.J. and Lertratanakul, A. and Papp, K. and Van den Bosch, F. and Tsuji, S. and Dokoupilová, Eva and Keiserman, M. and Bu, X. and Chen, L. and Mccaskill, R. and Zueger, P. and McdearmonandBlondell, E. and Pangan, A. and Tillett, W.},
doi = {http://dx.doi.org/10.1136/annrheumdis-2021-eular.1066},
keywords = {upadacitinib, psoriatic arthritis, Janus kinase inhibitor},
language = {eng},
title = {UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY},
url = {https://ard.bmj.com/content/80/Suppl_1/312.1},
year = {2021}
}
TY - CONF
ID - 1841042
AU - Mease, P.J. - Lertratanakul, A. - Papp, K. - Van den Bosch, F. - Tsuji, S. - Dokoupilová, Eva - Keiserman, M. - Bu, X. - Chen, L. - Mccaskill, R. - Zueger, P. - Mcdearmon-Blondell, E. - Pangan, A. - Tillett, W.
PY - 2021
TI - UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY
KW - upadacitinib, psoriatic arthritis, Janus kinase inhibitor
UR - https://ard.bmj.com/content/80/Suppl_1/312.1
N2 - Upadacitinib (UPA) is an oral Janus kinase inhibitor currently under evaluation for the treatment of psoriatic arthritis (PsA). Previous 24-week results from the SELECT-PsA 2 study in patients with PsA and prior inadequate response to ≥1 biologic disease-modifying antirheumatic drug (bDMARD) demonstrated UPA efficacy with a safety profile consistent with that observed in rheumatoid arthritis.
ER -
MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. BU, L. CHEN, R. MCCASKILL, P. ZUEGER, E. MCDEARMON-BLONDELL, A. PANGAN a W. TILLETT. \textit{UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY}. 2021. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2021-eular.1066.
|
